Publications en collaboration avec des chercheurs de Hospital Clinic Barcelona (20)

2023

  1. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

    Blood Advances

  2. Unraveling the genetics of transformed splenic marginal zone lymphoma

    Blood Advances, Vol. 7, Núm. 14, pp. 3695-3709

2022

  1. Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation

    British Journal of Haematology, Vol. 196, Núm. 1, pp. 146-155

  2. Detection of early seeding of Richter transformation in chronic lymphocytic leukemia

    Nature Medicine, Vol. 28, Núm. 8, pp. 1662-1671

  3. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma

    British Journal of Haematology, Vol. 196, Núm. 3, pp. 589-598

2021

  1. Anti-trbc1 antibody-based flow cytometric detection of t-cell clonality: Standardization of sample preparation and diagnostic implementation

    Cancers, Vol. 13, Núm. 17

  2. Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma

    European Journal of Cancer, Vol. 157, pp. 132-139

2020

  1. Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)

    British Journal of Haematology, Vol. 190, Núm. 6, pp. 854-863

  2. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

    Blood Cancer Journal, Vol. 10, Núm. 10

  3. STAT3 and STAT5B mutations in T/NK-cell chronic lymphoproliferative disorders of large granular lymphocytes (LGL): Association with disease features

    Cancers, Vol. 12, Núm. 12, pp. 1-20

2019

  1. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

    British Journal of Haematology, Vol. 185, Núm. 3, pp. 480-491

  2. Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia

    Haematologica, Vol. 104, Núm. 3, pp. 576-586

2018

  1. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia

    Leukemia, Vol. 32, Núm. 3, pp. 645-653

  2. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets

    Leukemia, Vol. 32, Núm. 3, pp. 675-684

  3. Posttransplant monomorphic Burkitt’s lymphoma: clinical characteristics and outcome of a multicenter series

    Annals of Hematology, Vol. 97, Núm. 12, pp. 2417-2424

  4. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis

    The Lancet Haematology, Vol. 5, Núm. 8, pp. e359-e367

  5. The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia

    Leukemia and Lymphoma, Vol. 59, Núm. 10, pp. 2318-2326

2017

  1. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

    Journal of Molecular Diagnostics, Vol. 19, Núm. 1, pp. 99-106

  2. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group

    British Journal of Haematology, Vol. 178, Núm. 5, pp. 699-708

2014

  1. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

    Leukemia, Vol. 28, Núm. 2, pp. 391-397